Novel small molecule inhibitors targeting renal cell carcinoma: Status, challenges, future directions

Area of Science:

• Oncology
• Medicinal Chemistry
• Pharmacology

Background:

• Renal cell carcinoma (RCC) is a prevalent and aggressive cancer with high mortality rates.
• Existing treatments like chemotherapy and radiotherapy are often ineffective due to RCC's resistance.
• There is a critical need for novel therapeutic strategies to improve RCC treatment outcomes.

Purpose of the Study:

• To review recent advancements in novel small molecule inhibitors for renal cell carcinoma (RCC) treatment.
• To explore the structural optimization, mechanisms of action, and anticancer activities of these inhibitors.
• To discuss the clinical translation prospects and future directions for small molecule inhibitors in RCC therapy.

Main Methods:

• Literature review of recent research on small molecule inhibitors targeting RCC.
• Analysis of structural properties and conformational relationships of identified inhibitors.
• Evaluation of potential mechanisms and anticancer activities reported in preclinical studies.

Main Results:

• Numerous small molecule inhibitors have demonstrated promising results against RCC.
• Key focus areas include structural optimization and understanding structure-activity relationships.
• These inhibitors exhibit potential anticancer activities and novel mechanisms of action.

Conclusions:

• Novel small molecule inhibitors represent a promising therapeutic avenue for renal cell carcinoma (RCC).
• Further research into their mechanisms and clinical application could significantly improve treatment efficacy and overcome resistance.
• These agents hold potential for enhancing the clinical translation of targeted therapies for RCC.